Karen Knudsen, Chief Executive Officer at Parker Institute for Cancer Immunotherapy, shared a post on LinkedIn:
“Well done, FDA! New draft guidance allowing MRD (minimal residual disease) to be used as a primary endpoint for accelerated approval in multiple myeloma is a major advance for science, and for patients.
If we do this right, breakthrough therapies can enter the clinic sooner, rather than waiting years for traditional survival endpoints to mature. In a disease where durable remission and curative approaches are increasingly plausible, time absolutely matters.
This also core to our ethos Parker Institute for Cancer Immunotherapy, where the key goal of our network of institutes and portfolio companies is to move patients to curative therapy… faster!”
More posts featuring Karen Knudsen.